1. 2022
  2. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials

    HIBISCUS Study Group, Jan 2022, In: The Lancet Gastroenterology and Hepatology. 7, 1, p. 17-27 11 p.

    Research output: Contribution to journalArticlepeer-review

  3. Азилсартан медоксомил/хлорталидон - новая эффективная гипотензивная комбинация

    Сережина, Е. К. & Обрезан, А. Г., 2022, In: КАРДИОЛОГИЯ: НОВОСТИ, МНЕНИЯ, ОБУЧЕНИЕ. 10, 3, p. 16-25

    Research output: Contribution to journalArticlepeer-review

  4. Новости конгресса Российского общества кардиологов

    Сережина, Е. К., Обрезан, А. Г. & Обрезан, А. А., 2022, In: КАРДИОЛОГИЯ: НОВОСТИ, МНЕНИЯ, ОБУЧЕНИЕ. 10, 3, p. 82-84

    Research output: Contribution to journalArticlepeer-review

  5. 2021
  6. A patient with atrial fibrillation and diabetes: Selecting the optimal anticoagulant therapy regimen

    Obrezan, A. G., Filippov, A. E. & Obrezan, A. A., 11 Jun 2021, In: Russian Journal of Cardiology. 26, 5, 4508.

    Research output: Contribution to journalArticlepeer-review

  7. New biomarkers of injury, inflammation and remodeling in the differential diagnosis of heart failure types

    Serezhina, E. K. & Obrezan, A. G., 17 Feb 2021, In: Russian Journal of Cardiology. 26, 1, p. 166-171 6 p.

    Research output: Contribution to journalArticlepeer-review

Previous 1...3 4 5 6 7 8 9 10 ...25 Next

ID: 173875